2006 Congressional Drug Control Budget and Policy Assessment
Author: United States. Congress. House. Committee on Government Reform
Publisher:
Published: 2006
Total Pages: 164
ISBN-13:
DOWNLOAD EBOOKRead and Download eBook Full
Author: United States. Congress. House. Committee on Government Reform
Publisher:
Published: 2006
Total Pages: 164
ISBN-13:
DOWNLOAD EBOOKAuthor:
Publisher: Government Printing Office
Published:
Total Pages: 1288
ISBN-13:
DOWNLOAD EBOOKAuthor:
Publisher: Government Printing Office
Published:
Total Pages: 1208
ISBN-13:
DOWNLOAD EBOOKAuthor: T. Michael Andrews
Publisher: University Press of America
Published: 2012-02-16
Total Pages: 157
ISBN-13: 0761857095
DOWNLOAD EBOOKThis book presents an insider’s view of the federal government’s dual mission to stop the flow of illegal drugs across our borders and to prevent streams of drug money from financing drug cartels, insurgents, and terrorists. Andrews focuses on current challenges facing federal drug enforcement agencies, how our strategies for enforcement have been redirected since 9/11, and why we require different strategies along our northern and southern borders and our ports of entry. This guide’s aim is to provide an operational view of drug enforcement to policymakers, law enforcement officials, think tanks examining drug interdiction issues, and military officials who assist federal law enforcement efforts. The Border Challenge will also be of interest to students of international development and social change and the next generation of criminal justice and law enforcement officials.
Author: Congressional Budget Office
Publisher: Lulu.com
Published: 2013-06-09
Total Pages: 65
ISBN-13: 1304121445
DOWNLOAD EBOOKPerceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation...
Author: United States. Congress. House. Committee on Government Reform
Publisher:
Published: 2006
Total Pages: 276
ISBN-13:
DOWNLOAD EBOOKAuthor: United States. Congress
Publisher:
Published: 1968
Total Pages: 1324
ISBN-13:
DOWNLOAD EBOOKAuthor: United States. Congress. House. Committee on Government Reform. Subcommittee on Criminal Justice, Drug Policy, and Human Resources
Publisher:
Published: 2005
Total Pages: 782
ISBN-13:
DOWNLOAD EBOOKAuthor: Citizens Against Government Waste
Publisher: Macmillan
Published: 2005-04-06
Total Pages: 212
ISBN-13: 9780312343576
DOWNLOAD EBOOKA compendium of the most ridiculous examples of Congress's pork-barrel spending.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
Published: 2017-09-28
Total Pages: 483
ISBN-13: 0309459575
DOWNLOAD EBOOKDrug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.